Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Authors:
- Xavier PivotXPXavier Pivot
- Joseph GligorovJGJoseph Gligorov
- Volkmar MüllerVMVolkmar Müller
- Peter Barrett-LeePBPeter Barrett-Lee
- Sunil VermaSVSunil Verma
- Ann KnoopAKAnn Knoop
- Giuseppe CuriglianoGCGiuseppe Curigliano
- Vladimir SemiglazovVSVladimir Semiglazov
- Guillermo López-VivancoGLGuillermo López-Vivanco
- Valerie JenkinsVJValerie Jenkins
- Nana ScottoNSNana Scotto
- Stuart OsborneSOStuart Osborne
- 1 September 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (10) , 962-970
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast CancerThe Journal of Clinical Pharmacology, 2013
- RU2 Potential Time Savings With Trastuzumab Subcutaneous (SC) Injection Versus Trastuzumab Intravenous (IV) Infusion: Results from Interviews Conducted As Part of a Time-and-Motion Study (T&M) Across 17 SitesValue in Health, 2012
- Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast CancerJournal of Clinical Oncology, 2011
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31Journal of Clinical Oncology, 2011
- Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical OutcomesJNCI: Journal of the National Cancer Institute, 2009
- Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical TrialsThe Journal of Clinical Pharmacology, 2009
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001